| Nov 15 |
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
|
| Nov 13 |
Cognition Therapeutics GAAP EPS of -$0.25
|
| Nov 13 |
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
|
| Nov 12 |
Life Sciences Investor Forum Agenda Announced for November 14th
|
| Nov 12 |
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
|
| Oct 31 |
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
|
| Oct 29 |
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
|
| Oct 23 |
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
|
| Oct 22 |
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
|
| Oct 9 |
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...
|
